meso-6k_20190405.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of April 2019

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(
Jurisdiction of incorporation or organization)

 

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

 


INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On April 5, 2019, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On April 5, 2019, Mesoblast Limited submitted a Final Director’s Interest Notice to the Australian Securities Exchange, a copy of which is attached to this report as Exhibit 99.2.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

 

 

 

 

 

 

 

 

Mesoblast Limited

 

 

 

 

 

 

/s/ Charlie Harrison

 

 

 

 

 

 

 

 

 

Charlie Harrison

 

 

 

 

Company Secretary

 

 

 

Dated: April 10, 2019


INDEX TO EXHIBITS

 

Item

 

 

 

 

 

99.1

99.2

 

Press release of Mesoblast Ltd, dated April 5, 2019.

Final Director’s Interest Notice, Brian Jamieson.

 

 

.

 

 

meso-ex991_6.htm

Exhibit 99.1

 

 

 

MESOBLAST TO PRESENT AT UPCOMING GLOBAL LIFE SCIENCE CONFERENCE IN LONDON

 

New York, USA; and Melbourne, Australia; April 5, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate presentation by the company at the H.C. Wainwright Global Life Sciences 2019 conference being held in London. The presentation is scheduled for Monday, April 8, 2019 at 11:50am GMT.

 

About Mesoblast

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) has leveraged its proprietary technology platform to establish a broad portfolio of late-stage allogeneic (off-the-shelf) product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com

 

 

For further information, please contact:

 

Julie Meldrum                                                  Schond Greenway

Corporate Communications                               Investor Relations

T: +61 3 9639 6036                                        T: +1 212 880 2060

E: [email protected]                     E: [email protected] 

 

 

 

Mesoblast Limited
ABN 68 109 431 870

 

www.mesoblast.com

Corporate Headquarters

Level 38

55 Collins Street

Melbourne 3000

Victoria Australia

 

T +61 3 9639 6036

F +61 3 9639 6030

United States Operations

505 Fifth Avenue

Third Floor

New York, NY 10017

USA

 

T +1 212 880 2060

F +1 212 880 2061

Asia

20 Biopolis Way

#05-01 Centros

Biopreneur 3

SINGAPORE 138668

 

T +65 6570 0635

F +65 6570 0176

 

 

 

 

 

 

 

 

 

 

 

 

 

meso-ex992_7.htm

 

Exhibit 99.2

Appendix 3Z

Final Director’s Interest Notice

 

 

 

Rule 3.19A.3

Appendix 3Z

 

Final Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available.  Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001

 

Name of entity Mesoblast Limited

ABN 68 109 431 870

 

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.  

 

Name of Director

Brian Jamieson

Date of last notice

8 January 2019

Date that director ceased to be director

31 March 2019

 

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Number & class of securities

 

(1) 150,000 options held directly; and

(2) 75,000 shares held directly.

 

 

 

 

 

 

 

+ See chapter 19 for defined terms.

 

11/3/2002 Appendix 3Z Page 1

 

 


Appendix 3Z

Initial Director’s Interest Notice

 

 

 

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

 

Name of holder & nature of interest

Note: Provide details of the circumstances giving rise to the relevant interest.

 

 

 

Number & class of Securities

 

 

 

570,000 shares held indirectly

 

 

 

 

 

 

Part 3 – Director’s interests in contracts

 

Detail of contract

Not applicable

Nature of interest

Not applicable

Name of registered holder

(if issued securities)

 

Not applicable

No. and class of securities to which interest relates

Not applicable

 

 

 

 

 

+ See chapter 19 for defined terms.

 

11/03/2002 Appendix 3Z Page 2